Human papillomaviruses (HPVs) are small, double-stranded DNA viruses that are 13 significant risk factors in the development of cancer, and HPV accounts for 14 approximately 5% of all worldwide cancers. Recent studies using data from The Cancer 15 Genome Atlas (TCGA) have demonstrated that elevated levels of estrogen receptor 16 alpha (ERα) are associated with improved survival in oropharyngeal cancers, and these 17 elevated receptor levels were linked with human papillomavirus positive cancers 18 (HPV+cancers). There has been a dramatic increase in HPV-related head and neck 19 squamous cell carcinomas (HPV+HNSCCs) over the last two decades and therapeutic 20 options for this ongoing health crisis are a priority; currently there are no anti-viral 21 therapeutics available for combating HPV+cancers. During our own TGCA studies on 22 head and neck cancer we had also discovered the overexpression of ERα in 23 HPV+cancers. Here we demonstrate that 17β-estradiol (estrogen) attenuates the 24 growth/cell viability of HPV+cancers in vitro, but not HPV negative cancer cells. In 25 addition, N/Tert-1 cells (foreskin keratinocytes immortalized with hTERT) containing 26 HPV16 have elevated levels of ERα and growth sensitivity following estrogen treatment 27 when compared with parental N/Tert-1. Finally, we demonstrate that there are 28 potentially two mechanisms contributing to the attenuation of HPV+ cell growth following 29 estrogen treatment. First, estrogen represses the viral transcriptional long control region 30 (LCR) downregulating early gene expression, including E6/E7. Second, expression of 31 E6 and E7 by themselves sensitizes cells to estrogen. Overall our results support the 32 recent proposal that estrogen could be exploited therapeutically for the treatment of 33 HPV positive oral cancers.
HPV+HNSCC.
48 49 Introduction 50 HPV is the most common sexually transmitted infection in the United States, infecting 51 nearly every sexually active person at some point in their lives (1) (2) (3) (4) (5) (6) (7) (8) . Of the high-risk transcripts in these cells, as reduction of E6 and E7 levels have the potential to 140 reactivate the p53 and pRb tumor suppressor pathways that would attenuate cellular 141 growth. Figure 2A demonstrates that in SCC47, UMSCC104 and UMSCC152 (an 142 HPV16+HNSCC line with a mixed population of integrated and episomal viral genomes) 143 estrogen treatment for 7 days results in a significant reduction in viral RNA transcript 144 levels. However, there was no significant reduction of the viral DNA levels in any of 145 these cell lines during this treatment ( Figure 2B ). The results from Figures 1&2 146 demonstrate that estrogen can selectively attenuate the growth of HPV16+HNSCC cell 147 lines and reduce the viral transcript levels in these cells.
148 An HPV16 isogenic model demonstrates that the presence of HPV16 imparts ERα 149 upregulation and estrogen sensitivity. 150 Previously we reported on the development of an HPV16 life cycle model in N/Tert-1 151 cells (24, 25) . In N/Tert-1+HPV16 cells there is an increase in ERα expression over that 152 in the parental N/Tert-1 cells ( Figure 3A ). The comparison between N/Tert-1 parent cells 153 and N/Tert-1+HPV16 cells allows an isogenic comparison of their response to external 154 reagents. Figure 3B demonstrates that control N/Tert-1 cell growth was not significantly 155 affected by estrogen treatment over a 6-day period; in comparison, both pooled and 156 9 clonally generated N/Tert-1+HPV16 cells were growth attenuated with estrogen 157 treatment ( Figure 3C ). We also have investigated HPV16 host gene regulation in human 158 tonsil keratinocytes immortalized by HPV16 (HTK+HPV16) and the growth of this cell 159 line is severely attenuated by estrogen ( Figure 3D) (26) . Expression of the viral RNAs 160 were downregulated by estrogen treatment in both N/Tert-1+HPV16 and HTK+HPV16 161 cells ( Figure 3E ). This is similar to the downregulation of viral RNA expression in the 162 HPV16+HNSCC lines (Figure 2A ).
163

Estrogen represses transcription from the HPV16 long control region (LCR)
. 164 Figures 2&3 demonstrate that estrogen treatment of HPV16+ cells results in the 165 repression of viral RNA expression. Transcription of HPV16 viral genes is regulated by 166 the Long Control Region (HPV16-LCR), a region that is regulated by a number of host 167 transcription factors. We constructed a reporter plasmid where luciferase gene 168 expression is regulated by the HPV16-LCR (pHPV16-LCR-Luc), transfected this vector 169 into C33a cells, and monitored transcription levels of the pHPV16-LCR-Luc via relative 170 fluorescence units (RFU) in the presence or absence of estrogen. Estrogen treatment 171 resulted in a significant reduction of luciferase expression ( Figure 4A ), while expression 172 from a control luciferase plasmid (pgl3 basic) was not affected by estrogen treatment.
173
Because of the effects observed in HeLa cells ( Figure 1C ), we sought to determine if 174 the LCR repression was also observed in HPV18 used a previously described pHPV18-175 LCR-luc plasmid(27); similar significant repression of the HPV18-LCR was also 176 observed ( Figure 4B ). We carried out similar experiments in N/Tert-1 cells where 177 estrogen treatment also significantly reduced luciferase activity in cells transfected with 178 pHPV16-LCR-Luc ( Figure 4C ), but did not reduce the control luciferase plasmid. The 179 10 conclusion from Figures 2-4 is that estrogen represses transcription from the HPV16 180 long control region to downregulate expression of early viral genes.
181
Estrogen increases DNA damage and initiates apoptosis in some HPV+ cancer 182 cells. 183 Downregulation of E6 and E7 expression by estrogen could result in the elevation of 184 p53 and pRb expression (their respective tumor suppressor targets)(28-41). Previously, 185 studies have shown that when E2 is overexpressed in HPV positive cervical cancer 186 cells it represses transcription from the viral LCR and this repression reduces E6 and 187 E7 levels and reactivates the p53 and pRb tumor suppressor proteins (31, (42) (43) (44) 50). Moreover, E2 overexpression and loss of E6/E7, results in the elevation of p53 and 189 pRb that allows for previously observed attenuation of growth in HeLa cells (23, 31, 45, 190 46, 48) . Similarly, our studies indicate estrogen treatment represses transcription from 191 the LCR to reduce expression of E6 and E7 levels. We therefore analyzed the protein 192 levels of p53 and pRb in our cancer cell lines in the presence or absence of estrogen, 193 as well as monitor γh2AX as a marker for the initiation of the DNA damage 194 response(51), and the ratio of cleaved-PARP1/PARP1 as a marker for apoptosis. These 195 western blots are presented in Figure 5A with accompanying densitometry analysis 196 ( Figure 5B ).
197
As expected, analysis of the response to estrogen in the sensitive HeLa cells revealed a 198 significant increase in p53, pRb, γh2AX, and PARP1 cleavage ( Figure 5A , top panel).
199
Confirming the previously observed increase in apoptosis following estrogen in HeLa 200 cells(23). Furthermore, analysis in the HPV-cancer cells reveals no dramatic alterations 201 in p53, pRb, or PARP1 cleavage; however, there is a significant increase in γh2AX in 202 C33a cells ( Figure 5A , middle panel). This increase in γh2AX reveals that estrogen is 203 still initiating DNA damage; however, it appears that this damage alone is not sufficient 204 to inhibit the growth of the C33a cells. Western blot analysis of our HPV+HNSCC lines 205 reveals a less than clear cut mechanism that allows for the reduction in cell growth Therefore, the reactivation of these tumor suppressors following estrogen treatment 211 does not fully explain the attenuation of cell growth in the HPV16+ cells.
212
Expression of the viral oncogenes promotes delayed cell growth attenuation
213 following estrogen treatment. 214 We next investigated whether the transcriptional reprograming of N/Tert-1 cells carried 215 out by HPV16 oncogenes alone could sensitize cells to estrogen and attenuate cellular 216 growth. To do this we expressed E6 or E7 or E6+E7 in N/Tert-1 cells and further 217 compared these cells to those expressing the full HPV16 genome (N/Tert-1+HPV16); 218 these E6, E7, and E6+E7 cell lines were generated using retroviral delivery and have 219 been described previously (26, 52) . Figure 6A Figure 6B ). As the expression of 226 the E6 and E7 in panels 5Aiii-v is not driven from the viral LCR, but rather from retroviral 227 sequences, we anticipated that the RNA levels of the oncogenes would not be regulated 228 by estrogen. This is indeed the case; estrogen treatment did not alter E6 or E7 levels in 229 the cells transduced with the retroviral vectors ( Figure 6C ). Therefore, the growth 230 attenuation of these cells following treatment with estrogen can be contributed to the 231 expression of the viral oncoproteins, and likely due to the transcriptional reprograming 232 of these cells carried out by these proteins.
233
Estrogen and radiation treatment of HPV positive and negative cancer cells. 234 Radiation treatment is a standard of care therapy for HPV+HNSCCs. We treated C33a,
235
HN30 and SCC47 cells with estrogen and then treated them with 2, 5 and 10 Gy of 236 radiation to investigate whether estrogen can promote further response to this 237 treatment. For C33a ( Figure 7A ) and HN30 ( Figure 7B ), the presence of estrogen made 238 no significant difference to the response to radiation treatment. For SCC47 cells, 239 treatment with estrogen by itself attenuated cell growth, as shown in Figure 1Bi . As 240 observed in Figure 7C , treatment with radiation did not have a dramatic effect on the 241 growth of SCC47. However, because SCC47 cells were highly sensitive to estrogen 242 alone, the additive effect observed with estrogen and radiation lead to ~80% loss in cell 243 viability even at 2 Gy radiation. This is promising and suggests that estrogen treatment 244 may provide a unique opportunity to allow for increased responsiveness to radiation 245 treatment in the clinic at reduced radiation doses for HPV+HNSCC. While the prophylactic vaccine should decrease the incidence of HPV in the upcoming 250 decades, we currently lack antiviral treatments to target those already infected with the 251 virus. Likewise, HPV-related HNSCC are on the rise and this oncogenic virus has 252 bypassed tobacco as the main carcinogen in the oropharyngeal region (3, 11, 53) .
253
Despite HPV+ and HPV-HNSCCs being very different both phenotypically and 254 genotypically in terms of their pathological and molecular mechanisms of 255 carcinogenesis and in their response to therapy, they are still treated the same in the 256 clinic(54). It is therefore of particular interest to develop HPV-specific treatments for 257 HPV+HNSCC.
258
Analysis of TCGA data showed that the expression of the estrogen receptor alpha 259 (ERα) was highly significantly upregulated in HPV16+HNSCC vs HPV-HNSCC(20, 21, 260 24). The ERα also decreased as stages advance, so we initially rationalized that 261 estrogen may play a role in the early development of cancer. This differential expression 262 of the ERα presented an opportunity to exploit a significant difference between HPV+/-263 HNSCC and to possibly develop a specific targeted approach. Our initial hypothesis 264 aligned with previous indications that the estrogen and the ERα increase the risk of 265 cervical cancer, and we further predicted that high doses of estrogen would initiate the 266 DNA damage response (DDR) (14-16, 18, 19, 55-58) . Based on our previously 267 published data, we further predicated that this increase in the DDR via estrogen would 268 enhance HPV tumorigenicity and ultimately result in worse outcomes and disease 269 progression(59). However, it soon became clear that our initial hypothesis was incorrect 270 when HPV+ cells were specifically sensitized via estrogen treatment, while HPV-cells 271 14 showed little to no response. We were also extremely surprised with the dramatic 272 response to estrogen that we observed in HeLa cells, although recently published data 273 now confirms our observations(23). This recent study utilizing HeLa cells as a model to 274 analyze steroid signaling confirmed these cells are particularly sensitive to estrogen. Li 275 et al showed that estrogen induced classical caspase-3-mediated apoptosis via a multi-276 step molecular mechanism, however this study did not take into account the HPV status 277 of their cell model and may have missed an underlying viral mechanism by which 278 estrogen was able to induce the cell death they observed(23). More specifically, HeLa 279 cells are intrinsically dependent on the expression of E6 and E7(60); if estrogen is able 280 to reduce viral levels of these vital oncoproteins, this could contribute to the rapid death 281 progression observed in HeLa cells, although it likely not the only mechanism.
282 While the expression of the ERα was found to be upregulated in HPV+HNSCC, and via 283 HPV expression in our N/Tert-1 model, we do not believe that the overall ERα 284 expression level is the only reason that HPV+ cells are sensitive to estrogen. Among 285 the cell lines we analyzed for estrogen sensitivity, the C33a cells had the highest protein 286 level as observed by western blot (Figure 1A ), yet C33a cells showed little to no cell 287 growth response to estrogen alone (Figure 1Biii ), however estrogen did increase γh2AX 288 demonstrating these cells are responsive to estrogen ( Figure 5A, middle panel) , while 289 only providing moderate sensitization to irradiation ( Figure 7A ). It is likely that 290 estrogen/HPV specific interactions, both via the LCR and E6/E7, are responsible for the 291 growth inhibition and cell death we observed in our HPV+ cell lines, not from DNA 
298
HPV+HNSCC is most commonly associated with males, found at a 4:1 higher ratio than 299 observed in females(61). While estrogen is typically associated with females, men do in 300 fact express appreciable levels of the estrogen receptors and circulating estradiol levels 301 in males are the same or higher than observed in post-menopausal women(62-65).
302
Therefore, this could begin to explain some of the sex related differences observed in 303 the instances of HPV+HNSCC and presents an interesting observation for future 304 studies.
305
It isn't clear what control region in the HPV16 LCR is responsible for transcriptional 306 repression following estrogen treatment. However, it has been shown that the ERα can 307 interact with AP1 via c-Jun and there are known AP1 binding sites in the HPV16 LCR 308 that may mediate the response of this region to estrogen(66-72). This will be 309 investigated in future studies.
310
Future studies determining the exact mechanism of the interaction between estrogen 311 and HPV may provide additional opportunities to provide more specific targeted 312 approaches to exploit this HPV specific sensitization to estrogen for therapeutic gain in 313 the treatment of HPV+cancers. Overall our results indicate that estrogen may provide 314 an approach that could be exploited therapeutically for the treatment of HPV+ epithelial Note cells were plated at 5 x 10 5 in 100-mm dishes. At the time of harvest, cells were washed twice with phosphate buffered saline (PBS).
394
RNA was immediately isolated using the SV Total RNA Isolation System (Promega) were analyzed for their expression of the ERα and compared to the loading control β-actin. HPV status is indicated above the blots. Experiments were conducted in triplicate and no significant correlation between HPV status and ERa expression was observed. B) HPV+ SCC47 (i) and UMSCC104 cells (ii), and HPV-C33a (iii) and HN30 (iv) were seeded on day zero and grown in the presence or absence of 15µM estrogen. Cells were trypsinized and counted on day 3 and day 6 and cell counts are presented on a logarithmic scale. Statistical differences in both SCC47 and UMSCC104 cell can be observed at both day 3 and day 6. *p<0.05 **p<0.001. No statistical difference is observed between treatments on day 3 or day 6 in C33a (iii) or HN30 cells (iv). Experiments were conducted in triplicate and error bars are representative of SE. C) (i) HeLa cells were grown in the presence or absence of 15µM estrogen for 72 hours then cells were counted for viability via trypan blue exclusion. (ii) Data is presented as % viability at 48 hours as measured by luciferase to monitor ATP via the Promega Cell Titer-Glo assay, over DMSO control. Experiments were conducted in triplicate and error bars are representative of SE. **p<0.001 **p<0.001.
Figure 4: Estrogen significantly represses HPV16 and HPV18 LCR transcription. A)
C33a cells were transfected with 1µg of pgl3 basic backbone (control), 1µg 16LCR-pGL3, or in B) 1µg 18-LCR-pGL3 and grown in the presence or absence of 15µM estrogen. C) N/Tert-1 cells were transfected with1µg of pgl3 basic backbone, or 1µg 16LCR-pGL3 and grown in the presence or absence of 15µM estrogen. Forty-eight hours post transfection, a luciferase-based assay was utilized to monitor levels of LCR transcription. Data is presented as RFU, normalized to total protein concentration as monitored by a standard BSA assay. **p<0.001 ***p<0.0001 : Estrogen enhances the response to radiation in SCC47 cells but not in C33a or HN30 cells. A) C33a B) HN30, and C) SCC47 cells were maintained in estrogen for 72 hours. Noted cells were then radiated with 2, 5, or 10 Gy radiation, and cells were trypsinized and counted by trypan blue exclusion for viability 72-hours post-irradiation. Data is presented as % viability compared with untreated control cells. Experiments were conducted in triplicate and error bars are representative of SE. **p<0.001.
